Citations

Clear

313 citation(s) found for "Alvarez, P".

AAPM task group report 351: Protocol for clinical reference dosimetry in external beam MR‐guided radiotherapy
Sarfehnia, Arman , Alvarez, P , Bellon, M, Bouchard, Hugo , Dolan, James E., Malkov, Victor , Asselen, Bram van , Wolthaus, J., Prez, Leon de , Dolan, James E., Ibbott, Geoffrey S. , Muir, Bryan , Rogers, D. W. O. , Yadav, Poonam

Mayo Clinic

Medical Physics | May 29, 2025 | Volume: 52 | Issue: 7 | Pages: No page available

10.1002/mp.17884 Get It

Abstract Background Magnetic Resonance‐guided Radiation Therapy (MRgRT) systems are increasingly used in clinical practice, necessitating a dedicated dosimetry protocol to address the challenges posed by the presence of strong magnetic fields. Purpose AAPM TG351 introduces a reference dosimetry protocol for external beam MRgRT systems, aligning with AAPM TG51 reports and incorporating elements from the IAEA TRS398 code of practice. Methods The protocol offers practical guidance on beam quality and dosimetry setup in the presence of strong magnetic fields. It reviews relevant literature to identify reference‐class chambers suitable for external beam MRgRT systems and determines their beam quality conversion and other relevant correction factors through a detailed analysis of available data and associated uncertainties. Results AAPM TG351 offers a comprehensive dosimetry protocol for external beam MRgRT systems, addressing the unique challenges posed by the presence of magnetic fields. It includes detailed guidance for measurement setups, a list of reference‐class chambers appropriate for reference dosimetry in MRgRT systems, and updated beam quality conversion and correction factors. Additionally, the protocol presents an in‐depth analysis of the uncertainty budget, identifying key contributors and providing strategies to minimize uncertainties, thereby enhancing clinical accuracy and reliability. Conclusions This protocol provides a practical, evidence‐based reference for medical physicists conducting reference dosimetry in external beam MRgRT systems.
Single-cell multiomics identifies both shared and unique features of immune dysfunction in Parkinson’s disease and inflammatory bowel disease colon, plasma and stool
Bolen, MacKenzie L. , Buendia, Marie‐Annick , Shi, Ji , Staley, Hannah A. , Kachergus, Jennifer M., Efron, Philip A. , Park, Gwoncheol , Nagpal, Ravinder , Alvarez, Stephan D. , Xue, Qing‐Shan, McFarland, Nikolaus R. , Zimmermann, Ellen M. , Forsmark, Christopher E. , Thompson, E. Aubrey, Buendia, Marc , Staley, Hannah , Menees, Kelly B , Tansey, Malú G , McFarland, Nikolaus R , Buendia, Marc, Salas, Azucena , Thompson, E. Aubrey, Tansey, Malú G.

Mayo Clinic

No container title available | May 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.29.651228 | PMID 40661410 Get It

Abstract Parkinson’s disease (PD) is the fastest growing neurodegenerative disease in the world 1 . Gastrointestinal (GI) dysfunction can occur decades before motor impairments and in up to 80% of individuals living with PD 2,3,4 . We investigated peripheral relationships that may underlie mechanisms along the gut-blood axis that contribute to PD pathogenesis. Single-cell multiomic spatial molecular imaging (SMI) of colonic tissue localized inflammatory injury within epithelial cells that appear to be associated with iron mishandling in both inflammatory bowel disease (IBD) and PD biosamples. We found that both the single-cell SMI of RNA and protein revealed parallel cross-modal dysregulation in the gut epithelium, in both IBD and PD biosamples. These data are accompanied by plasma (PD) and stool (IBD) protein depletion of CCL22. Our findings suggest iron mishandling along the gut barrier likely contributes to systemic inflammation, which may be the catalyst that primes circulating immune cells to body-first PD pathogenesis.
Peripheral Neuropathy Incidence in Children, and Adolescents and Young Adults With Cancer and Medicaid Insurance in California
Abrahão, Renata , Cooley, Julianne J.P. , Brunson, Ann , Alvarez, Elysia , Mahajan, Anjlee , Wun, Ted , Verma, Rashmi , Ruddy, Kathryn J. , Keegan, Theresa H.M. , Kahn, Justine M , Brunson, Ann , Alvarez, Elysia M , Mahajan, Anjlee , Wun, Ted , Verma, Rashmi , Ruddy, Kathryn J , Keegan, Theresa H M , Alvarez, Elysia Marie

Mayo Clinic

JCO Oncology Practice | April 22, 2025 | Volume: 22 | Issue: 2 | Pages: 225-234

10.1200/op-24-00748 | PMID 40262078 Get It

PURPOSE Chemotherapy-induced peripheral neuropathy is a potentially debilitating adverse effect of cancer therapy that can lead to delay, reduction, or discontinuation of cancer treatment. Population-based data on peripheral neuropathy incidence among young cancer survivors are lacking. METHODS Using a linkage between Medicaid, the California Cancer Registry, and hospitalization and emergency department data, we identified 6,028 adolescents and young adults (15-39 years) with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), breast cancer, colorectal cancer, or testicular cancer and 418 children (<15 years) with HL or NHL during 2005-2017. We determined the cumulative incidence of peripheral neuropathy and its association with neurotoxic chemotherapy identified from Medicaid claims, using multivariable Cox proportional hazards regression models. RESULTS Of 6,446 patients, 1,007 were diagnosed with peripheral neuropathy. Across each cancer type, incidence was higher among patients receiving neurotoxic drugs. For example, compared with non-neurotoxic agents, 5-year cumulative incidence was higher with oxaliplatin for colorectal cancer (24.0% v 6.2%) and paclitaxel for breast cancer (22.6% v 5.1%). In multivariable analysis, the agents most strongly associated with peripheral neuropathy were brentuximab (±other neurotoxic drugs) for HL (hazard ratio [HR], 9.53 [95% CI, 5.95 to 15.26]); brentuximab (±vinca alkaloids; HR, 7.00 [95% CI, 4.13 to 11.87]) for NHL, paclitaxel for breast cancer (HR, 4.03 [95% CI, 3.05 to 5.31]); oxaliplatin for colorectal cancer (HR, 3.46 [95% CI, 2.23 to 5.36]); and cisplatin and etoposide for testicular cancer (HR, 2.06 [95% CI, 1.37 to 3.11]). CONCLUSION The high incidence of peripheral neuropathy highlights the need for frequent monitoring, new supportive care approaches, and development of novel therapeutic agents to minimize toxicity while maintaining treatment efficacy.
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study
Balte, Pallavi , Sun, Yifei , Allen, Nori, Arynchyn, Alexander , Bowler, Russell P. , Elkind, Mitchell S, Garcia‐Bedoya, Olga , Garudadri, Suresh , Hansel, Nadia N. , Hermann, E.A. , Hoffman, Eric A. , Kaplan, Robert C. , Laine, Andrew F. , Lynch, David A. , Matsushita, Kunihiro , McKleroy, William , Naik, Sneha N. , O'Driscoll, O., Rusk, A.M., Salvatore, Mary , Smith, Benjamin M. , Sotres‐Alvarez, Daniela , Umans, Jason G. , Washko, George R. , Woodruff, Prescott G. , Ortega, Victor E. , Oelsner, Elizabeth C. , Balte, Pallavi P , Bowler, Russell P , San Jose Estepar, Raul , Hoffman, Eric A , Humphries, Stephen M , Krishnan, Jerry A , Podolanczuk, Anna J , Rusk, Annie, Wenzel, Sally E , Oelsner, Elizabeth C , Kim, John S. , Allen, Nori, Angelini, Elsa D. , Barr, R. Graham , Blaha, Michael Joseph , Carr, J. Jeffrey , Cole, Shelley A. , Couper, David , Demmer, Ryan T. , Doyle, Margaret F. , Estépar, Raúl San Jośe , Humphries, Stephen M. , Hunninghake, Gary M. , Lee, Joyce , Make, Barry J. , Min, Yuan‐I , O’Connor, George T. , Oren, Eyal , Podolanczuk, Anna J. , Post, Wendy S. , Pottinger, Tess D. , Regan, Elizabeth Anne , Schwartz, David A. , Vasan, Ramachandran S. , Wenzel, Sally E. , Xanthakis, Vanessa

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 16, 2025 | Volume: 211 | Issue: 7 | Pages: 1196-1210

10.1164/rccm.202408-1656oc | PMID 40238945 Get It

Abstract Rationale Increased risk of coronavirus disease (COVID-19) hospitalization and death has been reported among patients with clinical lung disease. Objectives To test the association of objective measures of prepandemic lung function and structure with COVID-19 outcomes in U.S. adults. Methods Prepandemic obstruction (FEV1/FVC &lt; 0.70) and restriction (FEV1/FVC ⩾ 0.7, FVC &lt; 80%) were defined based on the most recent spirometry exam conducted in 11 prospective U.S. general population–based cohorts. Severe obstruction was classified by FEV1 &lt; 50%. Percentage emphysema, percentage high-attenuation areas, and interstitial lung abnormalities were defined on computed tomography in a subset. Incident COVID-19 was ascertained via questionnaires, serosurvey, and medical records from 2020 to 2023 and classified as severe (hospitalized or fatal) or nonsevere. Cause-specific hazard models were adjusted for sociodemographics, anthropometry, smoking, comorbidities, and COVID-19 vaccination status. Measurements and Main Results Among 29,323 participants (mean age, 67 yr), there were 748 severe incident COVID-19 cases over median follow-up of 17.3 months from March 1, 2020. Greater hazards of severe COVID-19 were associated with severe obstruction (vs. normal; adjusted hazard ratio [aHR], 2.11; 95% confidence interval [CI], 1.02–1.27), restriction (vs. normal; aHR, 1.40; 95% CI, 1.12–1.76), and percentage emphysema (highest vs. lowest quartile; aHR, 1.64; 95% CI, 1.03–2.61), but not greater high-attenuation areas or interstitial lung abnormalities. COVID-19 vaccination provided greater absolute risk reduction in these groups. Results were similar in participants without smoking, obesity, or clinical cardiopulmonary disease. Conclusions Prepandemic severe spirometric obstruction, spirometric restriction, and greater percentage emphysema lung on computed tomography were associated with risk of severe COVID-19. These findings support enhanced COVID-19 risk mitigation for individuals with impaired lung health and warrant further mechanistic studies on interactions of lung function, structure, and vulnerability to acute respiratory illnesses.
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
Arenillas, Carlota , Celada, Lucía , Ruiz-Cantador, José , Calsina, Bruna , Datta, Debayan , García‐Galea, Eduardo , Fasani, Roberta , Moreno-Cárdenas, Ana Belén , Alba‐Linares, Juan José , Miranda, Berta , Martínez‐Montes, Ángel M. , Álvarez-Escolá, Cristina , Lecumberri, Beatriz , García, Ana González , Flores, Shahida K., Esquivel, Emmanuel , Ding, Yanli , Peitzsch, Mirko , Robles-Guirado, José-Ángel , Zapata, Rita Maria Regojo , Iglesias, Carmela , Dwight, Trisha , Oleaga, Amelia , Garrido‐Lestache, Elvira , Marín, María Jesús del Cerro , Martínez-Bendayán, Isaac , Álvarez-González, Enol , Cubiella, Tamara, Lourenço, Delmar Muniz , Pereira, Maria Adelaide Albergaria, Burnichon, Nelly , Broberg, Craig S. , Dickson, Paxton V. , Soriano, Joaquín Rueda , Dienstmann, Rodrigo , Villanueva, Josep , Capdevila, Jaume , Gimenez‐Roqueplo, Anne‐Paule , Bechmann, Nicole , Vaidya, Anand , Weghorn, Donate , Casteràs, Anna , Adameyko, Igor , Miranda-Barrio, Berta , González García, Ana , K Flores, Shahida , Regojo Zapata, Rita Maria , Pozo-Kreilinger, José Juan , Iglesias, Carmela , Dwight, Trisha , Muir, Christopher A , Oleaga, Amelia , Garrido-Lestache Rodríguez-Monte, Maria Elvira , Del Cerro, Maria Jesús , Martínez-Bendayán, Isaac , Álvarez-González, Enol , Cubiella, Tamara , Lourenço, Delmar Muniz , A Pereira, Maria Adelaide , Burnichon, Nelly , Buffet, Alexandre , Broberg, Craig , Dickson, Paxton V , Fraga, Mario F , Llorente Pendás, José Luis , Rueda Soriano, Joaquín , Buendía Fuentes, Francisco , Toledo, Sergio P A , Clifton-Bligh, Roderick , Dienstmann, Rodrigo , Villanueva, Josep , Capdevila, Jaume , Gimenez-Roqueplo, Anne-Paule , Favier, Judith , Nuciforo, Paolo , Young, W F , Bechmann, Nicole , Opotowsky, Alexander R , Vaidya, Anand , Bancos, Irina , Weghorn, Donate , Robledo, Mercedes , Casteràs, Anna , Dos-Subirà, Laura , Adameyko, Igor , Chiara, María-Dolores , Dahia, Patricia L M , Toledo, Rodrigo A , Fraga, Mario F. , Nucíforo, Paolo , Young, William F. , Bancos, Irina , Chiara, María‐Dolores , Dahia, Patricia L. M.

Mayo Clinic

Cancer Discovery | April 8, 2025 | Volume: 15 | Issue: 5 | Pages: 1037-1062

10.1158/2159-8290.cd-24-0943 | PMID 40199338 Get It

Abstract This study explores parallels between systemic hypoxia adaptation in high-altitude populations and tumorigenesis. We identified EPAS1, a gene critical for hypoxia adaptation in populations such as Tibetans and Sherpas, as playing a similar adaptive role in tumors arising under hypoxic conditions. Tumors from patients with chronic hypoxia displayed impaired DNA repair and frequent emergence of EPAS1 variants, with frequencies reaching up to 90%, echoing the positive selection seen in high-altitude dwellers. Mechanistically, EPAS1 gain-of-function mutations promote COX4I2 expression, reducing cellular oxygen consumption and supporting tumor proliferation in hypoxia. Analysis of clinical data from patients with hypoxia revealed tissue-specific and time-sensitive tumorigenic effects, particularly impacting oxygen-sensitive cells in the postnatal period. Our findings suggest that EPAS1-driven adaptation mechanisms in high-altitude populations provide a model for understanding tumor evolution under hypoxic stress, highlighting how genetic adaptations to diverse stressors in natural populations may yield insights into tumorigenesis and cancer progression. Significance: This study reveals a broad convergence in genetic adaptation to hypoxia between natural populations and tumors, suggesting that insights from natural populations could enhance our understanding of cancer biology and identify novel therapeutic targets. See related commentary by Lee, p. 875
Cost effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects ( EMERGE )—A randomised placebo‐controlled clinical trial
Gillespie, Paddy , Mahon, R , Newman, C. , Alvarez‐Iglesias, Alberto , Smyth, Andrew , O’Shea, Paula , Egan, Aoife M. , O’Donnell, Martin , Dunne, Fidelma , Newman, Christine , Egan, A M , O'Shea, Paula M , Gillespie, Paddy , Dunne, Fidelma P , Ferguson, John P. , Devane, Declan

Mayo Clinic

Diabetic Medicine | April 4, 2025 | Volume: 42 | Issue: 6 | Pages: No page available

10.1111/dme.70036 | PMID 40173275 Get It

Abstract Aims To investigate the cost‐effectiveness of early initiation of metformin and usual care for gestational diabetes mellitus (GDM). Methods Economic evaluation from a healthcare perspective, based on the EMERGE randomised controlled trial. In total, 535 women with GDM were randomised to placebo in addition to usual care or metformin in addition to usual care. Economic outcomes included incremental healthcare costs and quality adjusted life years ( QALYs ) and expected cost‐effectiveness at cost‐effectiveness threshold values of €20,000, €45,000 and €100,000 per QALY gained. Uncertainty was explored using parametric, non‐parametric, deterministic and probabilistic methods and heterogeneity using subgroup analysis. Results On average, relative to the placebo arm, the early metformin arm was associated with non‐statistically significant mean increases of €193.07 (95% CI : −€789.88, €1176.01; p = 0.700) and 0.002 QALYs (95% CI : −0.009, 0.013; p = 0.771). In terms of expected cost‐effectiveness at threshold values of €20,000, €45,000 and €100,000 per QALY gained, the probability of the early metformin arm being more cost‐effective was estimated at 0.423, 0.452 and 0.524. Exploratory subgroup analyses provided more favourable but not definitive evidence in favour of the early metformin arm for cohorts with previous GDM and previous caesarean section. Conclusions We do not find definitive evidence that early initiation of metformin in addition to usual care for GDM was more cost‐effective than usual care alone. The clinical and economic evidence may be considered equivocal, but worthy of further examination.
Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders
Yang, Lin , Lin, Wan-Hsin, Feathers, Ryan W. , Ayers-Ringler, Jennifer , Tolosa, Ezequiel J. , Kizhake, Amritha G., Kizhake, Smitha , Kubica, Sydney P., Boghean, Lidia , Naldrett, Michael J. , Rana, Sandeep , Schaefer-Klein, Janet, Roden, Anja C. , Kosari, Farhad , Anastasiadis, Panos Z. , Feathers, Ryan, Tolosa, Ezequiel, Roden, Anja, Natarajan, Amarnath , Mallareddy, Jayapal Reddy , Lin, Wan‐Hsin , Alvarez, Sophie , Singh, Sarbjit , Zahid, Muhammad , Borad, Mitesh J. , Natarajan, Amarnath , Mansfield, Aaron S.

Mayo Clinic

RSC Advances | April 4, 2025 | Volume: 15 | Issue: 13 | Pages: 10419-10425

10.1039/d5ra01441g | PMID 40182503 Get It

Despite ongoing efforts to employ structure-based methods to discover targeted protein degraders (TPD), the prevailing strategy remains synthesizing a focused set of heterobifunctional compounds and screening them for target protein degradation.
A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021
Jacobs, Jeremy W. , Adkins, Brian D. , Stanek, C , Stephens, Laura D. , Daou, Laetitia , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Aljuboori, Omar , Harrington, Thomas J., Byrnes, Diana M. , Eichbaum, Quentin , Klapper, Ellen, Klein, Monica S., Alkhateb, Rahaf, Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bloch, Evan M. , Adkins, Brian D. , Booth, Garrett , Stanek, Caroline G , Grossman, Brenda J , Stephens, Laura , Crowe, Elizabeth P , Marques, Marisa B , Yamada, Chisa , Juskewitch, Justin E , Perez-Alvarez, Ingrid , Parsons, Meredith G , Schlueter, Annette J , Tormey, Christopher A , Yates, Sean G , Bloch, Evan M , Raval, Jay S , Jacobs, Jeremy W , Adkins, Brian David , Adkins, Brian D. , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Marques, Marisa B. , Yamada, Chisa , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Aldarweesh, Fatima , Parsons, Meredith G , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Raval, Jay S.

Mayo Clinic

Journal of Clinical Apheresis | March 30, 2025 | Volume: 40 | Issue: 2 | Pages: No page available

10.1002/jca.70017 | PMID 40145682 Get It

ABSTRACTImmune thrombotic thrombocytopenic purpura (iTTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion secondary to acquired ADAMTS13 deficiency. Contemporary data regarding iTTP treatment practices in the US, including the use of caplacizumab, are lacking. We aimed to characterize the demographics and therapies, including medications and apheresis practices, in patients with iTTP in the US. We retrospectively analyzed iTTP cases at 15 sites in the US that provide comprehensive care for patients with iTTP. The time‐period assessed was from January 1, 2017 to December 31, 2021. Our primary objective was to analyze data by iTTP episode, inclusive of initial episodes and relapses. A total of 390 iTTP episodes were reported for 280 unique individuals (187 females, 93 males). Thirty‐day mortality was 3.7% (14/374), and 6‐month mortality was 7.4% (27/367). TPE details were reported for 343 episodes, among which 261 underwent at least one procedure (median 6, IQR 3–11). Among the 261 episodes with at least one therapeutic plasma exchange (TPE) performed, 82.0% (214/261) used only plasma. Caplacizumab was used either alone or in combination with other agents in 43 (11.0%) episodes. Management strategies for iTTP remain varied across centers in the US, with a variety of combinations for TPE replacement fluids and therapeutic agents, as well as limited use of caplacizumab. Further research and standardization of treatment regimens may further reduce mortality in this condition.
Utilizing Patient Input in Rectal Cancer Trial Design
Alvarez, Janet , Zambare, Wini , George, Manju, Garcia, Reese , Gallagher, Phuong , Kitchens, Caleah , Bercz, Aron , Kim, Min Jung , Romesser, Paul B. , Cercek, Andrea , Sanoff, Hanna K. , Hong, Theodore S. , Baghdadi, Tareq Al, Shergill, Ardaman , Meyerhardt, Jeffrey A. , Horvat, Natally , Hall, William A., Smith, J. Joshua , Sanoff, Hanna , George, Thomas J , Hong, Theodore S , Yothers, Greg , Philip, Philip , Alese, Olatunji B , Shergill, Ardaman , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Horvat, Natally , Dasari, Arvind N , Shi, Qian , Schrag, Deborah , Smith, J Joshua , Romesser, Paul B , Baghdadi, Tareq Al , Kitchens, Caleah , García‐Aguilar, Julio , George, Thomas J. , Yothers, Greg , Philip, Philip A. , Alese, Olatunji B. , O’Reilly, Eileen M. , Dasari, Arvind , Shi, Qian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 20, 2025 | Volume: 117 | Issue: 7 | Pages: 1421-1428

10.1093/jnci/djaf074 | PMID 40108482 Get It

Abstract Background The treatment of locally advanced rectal cancer now includes “watch-and-wait” (WW) management for patients who exhibit a clinical complete response (cCR) to total neoadjuvant therapy (TNT). We assessed patients’ knowledge and preferences regarding WW with the goal of incorporating patient input into clinical trial design. Methods Rectal cancer patients in advocacy groups (COLONTOWN/Rectalburgh and Fight CRC) were surveyed regarding perceptions about treatment strategies, tolerable risks of treatment failure, and preferences on clinical trial design. Surveys were initially distributed in 2019, with the shift toward WW prompting re-survey of select questions in 2023. Results All respondents preferred enrollment in trials that incorporated patient input. Most respondents (76%) preferred treatment that incorporated chemotherapy escalation over radiation escalation. Furthermore, when presented with a hypothetical patient who developed a cCR after chemoradiation (without the option for WW), 58% of patients chose surgical treatment (with 100% risk of permanent ostomy and 80% chance of cure) over omission of surgery (with &lt;80% chance of cure). In contrast, when the hypothetical patient developed a cCR after TNT (with an option for WW), 82% of patients opted for selective WW over surgery. Conclusions This work successfully integrated patient advocacy groups as a resource for obtaining patient input. Surveys revealed patients had a strong preference for chemotherapy escalation, for selective WW when offered, and for incorporation of input into future clinical trial design. These findings describe how well-informed patients approach complex medical decision-making and serve as a starting point for future studies seeking to incorporate patient voices.
Epidemiologic profile of community-acquired Clostridioides difficile infections: a systematic review and meta-analysis
Ruiz-Hernández, Fernando G. , Méndez-Arellano, Ana Camila, Azamar-Márquez, Jhoan Manuel , Camacho-Ortíz, Adrián , Alvarez-Villalobos, Neri Alejandro, Ruiz Hernandez, Fernando Gerardo , Camacho-Ortiz, Adrián , Álvarez‐Villalobos, Neri Alejandro

Mayo Clinic

Epidemiology and Infection | March 4, 2025 | Volume: 153 | Issue: No issue available | Pages: No page available

10.1017/s0950268825000202 | PMID 40033994 Get It

Abstract Clostridiodes difficile’s epidemiology has evolved over the past decades, being recognized as an important cause of disease in the community setting. Even so, there has been heterogeneity in the reports of CA-CDI. Therefore, the aim of this study was to assess the epidemiologic profile of CA-CDI. This systematic review and meta-analysis were conducted according to PRISMA checklist and Cochrane guidelines (CRD42023451134). Literature search was performed by an experienced librarian from inception to April 2023, searching in databases like MEDLINE, Scopus, Web of Science, EMBASE, CCRCC, CDSR, and ClinicalTrials. Observational studies that reported prevalence, incidence of CA-CDI, or indicators to calculate them were included. Pool analysis was performed using a binomial-normal model via the generalized linear mixed model. Subgroup analysis and publication bias were also explored. A total of 49 articles were included, obtaining a prevalence of 5% (95% CI 3–8) and an incidence of 7.53 patients (95% CI 4.45–12.74) per 100,000 person-years. In conclusion, this meta-analysis underscores that among the included studies, the prevalence of CA-CDI stands at 5%, with an incidence rate of 7.3 cases per 100,000 person-years. Noteworthy risk factors identified include prior antibiotic exposure and age.